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†Appendix 1.
Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with
presymptomatic carriers from families representing those at risk. While cerebral blood ﬂow shows differences between frontotem-
poral dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal
dementia. This study aimed to delineate the cerebral blood ﬂow signature of presymptomatic, genetic frontotemporal dementia
using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated
cross-sectional differences in arterial spin labelling MRI-based cerebral blood ﬂow between presymptomatic C9orf72, GRN or
MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses.
Cerebral blood ﬂow within regions of interest derived from this model was then explored to identify differences between individual
gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a
signiﬁcant inverse association between cerebral blood ﬂow and the expected age of symptom onset in carriers, but not non-carriers.
Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as
well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for
partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup.
These cerebral blood ﬂow differences ﬁrst appeared approximately 12.5 years before the expected symptom onset determined on
an individual basis. Cerebral blood ﬂow was lower in presymptomatic mutation carriers closer to and beyond their expected age of
symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a
promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
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Introduction
Frontotemporal dementia encompasses a pathologically
heterogeneous group of neurodegenerative diseases, charac-
terized clinically by prominent behavioural and/or language
disruption. Frontotemporal dementia signiﬁcantly impacts
patients and their families during the prime of their lives
when individuals have responsibilities to their careers, rais-
ing children and social interactions (Neary et al., 2005;
Onyike and Diehl-Schmid, 2013). It is highly heritable,
with an autosomal dominant family history documented
in about one-third of people with the disease (Rohrer
et al., 2009). Several mutations across three genes
(C9orf72, GRN and MAPT) make up the majority of gen-
etic frontotemporal dementia (Seelaar et al., 2011b; Warren
et al., 2013). The study of presymptomatic mutation car-
riers compared to non-carriers affords a unique opportun-
ity to understand more about the natural history of genetic
frontotemporal dementia during the preclinical phases.
One priority in frontotemporal dementia research is to
develop imaging biomarkers (Neary et al., 2005; Rohrer
et al., 2013). It is hoped that such biomarkers of genetic
frontotemporal dementia could identify those at highest
risk of transitioning into the clinical phase, the clinical sub-
type that will develop, and the age when symptoms will
appear. Furthermore, these biomarkers may allow for lon-
gitudinal monitoring of disease progression, as well as eval-
uating efﬁcacy of potential disease-modifying drugs (Cenik
et al., 2011; Bateman et al., 2012). Indeed, brain changes
have been demonstrated with imaging in presymptomatic/
early stage genetic Alzheimer’s disease (Bateman et al., 2012).
Our structural MRI work on presymptomatic/early stage
genetic frontotemporal dementia, as well as that of
others, has previously shown early brain changes, particu-
larly in the fronto-insular-temporal regions (Rohrer et al.,
2015; Lee et al., 2017; Bertrand et al., 2018). A potential
functional imaging biomarker is arterial spin labelling
(ASL) perfusion MRI. Increasing evidence suggests that per-
fusion changes in frontotemporal dementia may be more
extensive than structural brain changes early on in the dis-
ease course (Olm et al., 2016). ASL allows non-invasive
imaging of cerebral blood ﬂow in vivo (Alsop et al.,
2015). In contrast to other perfusion imaging techniques,
ASL uses blood water as an endogenous tracer, which is
safe and ideal for longitudinal imaging (Alsop et al., 2015).
Several studies have shown that ASL cerebral blood ﬂow
can distinguish symptomatic frontotemporal dementia cases
from controls and other dementias (Hu et al., 2010;
Shimizu et al., 2010; Binnewijzend et al., 2014; Olm
et al., 2016; Steketee et al., 2016). To our knowledge,
only one study conducted at a single site has examined
the use of ASL perfusion MRI in contrasting presympto-
matic MAPT and GRN mutation carriers (n = 34 com-
bined) to non-carriers (n = 31) (Dopper et al., 2016).
Whilst they did not ﬁnd any cross-sectional differences in
perfusion between carriers and non-carriers at baseline,
they demonstrated a signiﬁcant reduction in perfusion of
the frontal pole, superior frontal gyrus, paracingulate
gyrus, posterior (mid)cingulate gyrus, precuneus, and thal-
amus among GRN carriers compared to non-carriers on 2
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year follow-up scans (Dopper et al., 2016). Furthermore, a
signiﬁcant longitudinal decline in perfusion was observed in
frontal, temporal, parietal, and subcortical regions (Dopper
et al., 2016). Whilst the results are interesting, they may be
unduly limited by the sample size, did not include a robust
correction for partial volume effects, and the fact that they
did not account for relatedness of the participants in their
study design. Herein, we extend on this initial work by
investigating the ASL cerebral blood ﬂow signature of pre-
symptomatic frontotemporal dementia in unaffected at-risk
family members (n = 107 mutation carriers versus n = 113
mutation negative controls) participating in the multicentre
GENetic Frontotemporal dementia Initiative (GENFI). The
aims of this study were: (i) to delineate the cerebral blood
ﬂow signature of presymptomatic, genetic frontotemporal
dementia using a voxel-based analysis; (ii) to evaluate the
effects of genetic subgroup on the regional cerebral blood
ﬂow signature; and (iii) to estimate the chronological time
frame when presymptomatic changes are observed. We
hypothesized an inverse association between perfusion
and age, irrespective of mutation carrier status.
Furthermore, we posit that the strength of this association
will be more prominent in the presymptomatic carriers than
in non-carriers and will more strongly relate to their esti-
mated age of expected symptom onset than age alone.
Materials and methods
Participants
Data were drawn from the second data freeze of GENFI
(Rohrer et al., 2015), which consisted of centres in the UK,
Italy, The Netherlands, Sweden, Portugal and Canada. GENFI
participants included known symptomatic carriers of a patho-
genic mutation in C9orf72, GRN or MAPT and their ﬁrst-
degree relatives who were at risk of carrying a mutation, but
who did not show any symptoms (that is, presymptomatic).
Non-carriers were ﬁrst-degree relatives of symptomatic car-
riers who did not carry the mutation. The inclusion and ex-
clusion criteria are described in detail elsewhere (Rohrer et al.,
2015). As part of the standard GENFI protocol, subjects and
a close contact of them were interviewed by a neurologist
using a checklist of symptoms relating to frontotemporal de-
mentia. Symptoms were rated as absent, questionable/very
mild, mild, moderate or severe in nature and ratings were
corroborated by both the patient and their close contact.
Presymptomatic individuals scored for the most part as
having symptoms absent and, on occasion, in the very mild/
questionable range. They also could not have any cognitive,
behavioural or language deﬁcits that resulted in a functional
decline in terms of both their basic and/or instrumental activ-
ities of daily living. Ethical review boards from participating
centres approved the GENFI protocol and all participants
provided written informed consent according to the
Declaration of Helsinki. Data were collected between
January 2012 and March 2015 at nine GENFI sites and
based on acquiring 3T ASL and T1-weighted MRI images
in 294 participants. Symptomatic carriers (32 individuals)
were excluded from the primary analysis (see statistical ana-
lysis section below) since the focus of this study was on the
presymptomatic stage. However, as outlined below, perfusion
data from symptomatic carriers were included in a secondary
analysis. Our semi-automatic quality control procedure (out-
lined below) excluded 42 scans due to motion and other arte-
facts. Data from 220 presymptomatic participants were
included in the primary analysis (Table 1 and
Supplementary Fig. 1).
Table 1 Descriptive characteristics (n = 220)
Demographics Non-carriers
(n = 113, 51.4%)
Presymptomatic mutation carriers
(n = 107, 48.6%)
Test statistic
Age (years) 50.1  14.3 46.1  11.5 t(218) = 2.24, P = 0.03
Sex (male) 41 (36.3%) 41 (38.3%) 2(1) = 0.09, P = 0.76
Handedness (right dominant) 103 (91.2%) 96 (89.7%) 2(1) = 0.13, P = 0.72
Education (years) 14.1  3.1 14.2  3.0 t(218) = 0.22, P = 0.83
Average years from expected symptom onset 9.3  14.4 11.0  11.8 t(218) = 0.92, P = 0.36
Carrier status based on genetic subgroup
C9orf72 34 (30.1%) 34 (31.8%) 2(1) = 0.07, P = 0.79
GRN 68 (60.2%) 55 (51.4%) 2(1) = 1.72, P = 0.19
MAPT 11 (9.7%) 18 (16.8%) 2(1) = 2.41, P = 0.12
Cognitive and behavioural measures
Mini-Mental State Examination (/30) 29.2  1.1 29.1  1.4 t(197) = 0.91, P = 0.36
Cambridge Behavioural Inventory-Revised (/180) 3.9  5.7 4.8  10.1 t(193) = 0.74, P = 0.46
Frontotemporal Dementia Rating Scale (categoriesa) 0 (IQR 0–0) 0 (IQR 0–0) –
Data are n (%) or mean  standard deviation. Statistics for differences between non-carriers and presymptomatic mutation carriers are shown in the fourth column.
IQR = interquartile range.
aFrontotemporal Dementia Rating Scale categories = 0 (very mild), 1 (mild), 2 (moderate), 3 (severe), 4 (very severe), and 5 (profound); this scale was designed to be used in
symptomatic subjects and so there is a floor effect when applied to presymptomatic subjects leading them to be classified in the very mild range even though they do not have
significant functional involvement.
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Mutation testing
DNA extraction took place at local sites according to their
standard procedures. Mutation testing of participants also
took place at local sites either through direct DNA sequencing
or allele-speciﬁc PCR-based screening of GRN or MAPT.
C9orf72 hexanucleotide repeat expansions were evaluated
using a two-step genotyping procedure as previously described
(Dejesus-Hernandez et al., 2011). A pathogenic expansion of
C9orf72 was considered as having more than 30 repeats.
Image acquisition
T1-weighted and ASL acquisition sequences were harmonized
across scanners from different sites, as best as possible (Rohrer
et al., 2015). The product ASL sequences are fundamentally
different between vendors, thus we opted for four implemen-
tations to achieve best results: pseudo-continuous ASL
(PCASL) 3D fast-spin-echo stack-of-spirals implemented on a
3T General Electric MR750 (one site, n = 22); PCASL 2D gra-
dient-echo echo-planar imaging (EPI) on a 3T Philips Achieva,
with (one site, n = 99) and without (two sites, n = 32) back-
ground suppression; and a pulsed ASL 3D gradient-and-spin-
echo (GRASE) on 3T Siemens Trio systems (ﬁve sites, n = 67).
ASL parameters are described elsewhere (Mutsaerts et al.,
2018).
ASL image processing
We used ExploreASL to process the multicentre ASL data
(Mutsaerts et al., 2015), a toolbox based on Matlab
(MathWorks, MA, USA), Statistical Parametric Mapping 12
(SPM12, Wellcome Trust Centre for Neuroimaging, University
College London, UK) and Diffeomorphic Anatomical
Registration analysis using Exponentiated Lie algebra (DARTEL)
(Ashburner, 2007).
GENFI ASL image processing was optimized to process data
from multiple sites, vendors and sequences (Mutsaerts et al.,
2018). Brieﬂy, enhanced tissue priors (Lorio et al., 2016) were
used to segment the baseline T1-weighted images into grey and
white matter tissue probability maps, which were used to
create a population-based DARTEL template (Ashburner,
2007; Stonnington et al., 2008). Motion correction was per-
formed for ASL datasets using a 3D rigid-body transformation
with threshold-free motion outlier exclusion based on a thresh-
old-free optimization of the median grey matter voxel-wise
temporal signal-to-noise ratio (Wang et al., 2008; Shirzadi
et al., 2015). The M0 images were masked and smoothed,
and cerebral blood ﬂow was quantiﬁed using a single compart-
ment quantiﬁcation model (Alsop et al., 2015). The cerebral
blood ﬂow images were registered to the grey matter image
(Mutsaerts et al., 2018). Temporal standard deviation images
were used to visually inspect for artefacts that required data
ﬁltering (performed by H.J.M.M.M.) (Viviani et al., 2009).
ASL images were reviewed in a two-step procedure. First,
vascular regions with negative signal were identiﬁed by select-
ing clusters whose mean cerebral blood ﬂow was below a
threshold that was deﬁned as four times the median absolute
difference below the median. These voxels were clustered if
they were contiguous negative cerebral blood ﬂow values.
The signal intensities within the cluster were then sign ﬂipped.
Subsequently, voxels with extremely large values were identi-
ﬁed by thresholding the cerebral blood ﬂow image at 480%
sorted intensities. This upper threshold was based on a value
of four times the median absolute difference above the median.
To reduce the inﬂuence of these high macrovascular values,
while retaining some physiological variability, all values on
the cerebral blood ﬂow image above this threshold were
non-linearly rescaled (i.e. compressed) rather than hard-
clipped. The total number of adapted negative and positive
perfusion voxels in our sample was only a small proportion
of the whole brain mask, i.e. 4.5  3.4%.
ASL quality control
For inclusion of scans, a novel semi-automatic quality control
method was used (Supplementary Fig. 2). This method ranks
scans by their spatial coefﬁcient of variation (CoV) (Mutsaerts
et al., 2017), which reﬂects the amount of arterial transit time
artefacts. After excluding the worst quality scans (unusable) by
visual assessment, all remaining scans were categorized into: (i)
‘good’ (CoV40.6, cerebral blood ﬂow signal predominates
Figure 1 Statistical parametric maps derived from voxel-based mixed effects linear regression model examining the inter-
action effect between presymptomatic mutation status (carrier versus non-carrier) and years to age of expected symptom
onset. Significant clusters were defined using a P5 0.005 primary threshold and a P5 0.05 FWE cluster-forming threshold (cluster-size = 225
voxels). Both the t-statistic maps (A) and anatomical labels for clusters used in the post hoc region of interest analysis (B) are shown. Images are
shown in radiological space, overlaid on the mean population 3D T1-weighted image. c = cortex; g = gyrus; ROI = region of interest.
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artefacts); (ii) ‘acceptable’ (0.64CoV40.8, both cerebral
blood ﬂow signal and artefacts visible); or (iii) ‘bad’
(CoV4 0.8, artefacts predominate cerebral blood ﬂow
signal). Three authors (Z.S., A.D.R. and H.J.M.M.M.), each
with 3–6 years of experience in handling ASL data, independ-
ently reviewed and corrected the CoV-based categorization of
the images. Inconsistencies were resolved by consensus. Only
the 220 ‘good’ scans were included in the primary analyses
(Supplementary Fig. 2).
To adjust for site differences, we performed a spatially vary-
ing intensity normalization, which uses the within-site cerebral
blood ﬂow similarity between participants to remove the be-
tween-site quantiﬁcation differences. To facilitate this intensity
normalization, scanners that contributed 55 artefact-free scans
were excluded in the quality control step (nine scans in total).
Residual site effects were minimized by spatial intensity nor-
malization using site-speciﬁc bias-ﬁelds, as follows: (i) a mean
cerebral blood ﬂow image was created for each site; (ii) this
image was smoothed with a 6.4mm full-width at half-maximum
(FWHM) Gaussian kernel, constrained by a Montreal
Neurological Institute (MNI) brain mask; (iii) these site-speciﬁc
smoothed mean cerebral blood ﬂow images were averaged to
create a population-average cerebral blood ﬂow image, which
was rescaled to a mean grey matter cerebral blood ﬂow of
60ml/100g/min; (iv) site-speciﬁc bias-ﬁelds were created by divid-
ing the population-average cerebral blood ﬂow image with the
site-speciﬁc cerebral blood ﬂow image; and (v) individual cerebral
blood ﬂow images were multiplied by site-speciﬁc bias ﬁeld maps.
The voxel-based analysis was restricted to voxels that had
both adequate ASL signal-to-noise ratio (Viviani et al., 2009)
and were segmented as grey matter with probability 420%.
Statistical analysis
We compared demographic and clinical characteristics between
presymptomatic mutation carriers and non-carriers using
t-tests for continuous and chi-square tests for categorical vari-
ables. In our primary analyses, we used linear mixed-effects
models to test for cerebral blood ﬂow differences between
presymptomatic non-carriers and mutation carriers in voxel-
based and regional analyses. This model accounted for ﬁxed
and random effects of predictor variables, including intercept
terms (Sullivan et al., 1999; Rohrer et al., 2015; Masellis et al.,
2016). The ﬁxed effect predictor variables of interest were mu-
tation carrier status, years to age of expected symptom onset,
and the interaction between mutation carrier status and years
to age of expected symptom onset. Years to age of expected
symptom onset was calculated from the mean age at onset in
symptomatic family members—e.g. someone aged 50 years at
the time of assessment with a mean age at symptom onset of
55 years in their family would have a years to age of expected
symptom onset of –5 years (Rohrer et al., 2015). Family mem-
bership was included in the model as a random effect, as it
was expected that members from the same family might have
covariance in brain perfusion due to a shared genetic and en-
vironmental background (Rohrer et al., 2015). Sex and site
were also added as ﬁxed effect covariates. Age was included
as a covariate in a preliminary model but was removed
through a model building step because it was captured
almost entirely by the years to age of expected symptom
onset variable. In a sensitivity analysis, the described model
was also run replacing years to age of expected symptom
onset with age. The covariance matrix of family relatedness,
Figure 2 Linear mixed effects model regression lines for each of the six regions of interest plotting cerebral blood flow based
on years to age of expected symptom onset in presymptomatic mutation carriers (red) and non-carriers (blue). Shaded areas
represent the 95% confidence intervals.
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stratiﬁed by study site, is shown in Supplementary Fig. 1. All
analyses on the demographic, clinical, and regional perfusion
data were carried out using the Stata Software Version 14.1
(StataCorp, College Station, TX, USA).
Voxel-based analysis and subsequent
derivation of regions of interest
The regions where cerebral blood ﬂow was signiﬁcantly differ-
ent between presymptomatic carriers and non-carriers were
identiﬁed from the voxel-based analysis. Images were
smoothed, constrained by the voxel-based mask, with a
3.4mm FWHM Gaussian kernel (Dopper et al., 2016). The
primary cluster-forming threshold was P = 0.005, with the
extent threshold set at P = 0.05 for family-wise error (FWE)
correction. Regions of lower perfusion identiﬁed in the voxel-
based analysis in presymptomatic carriers compared to non-
carriers based on their years to age of expected symptom onset
were named according to their overlap with the Harvard-
Oxford atlas (Desikan et al., 2006). These voxel-based identi-
ﬁed areas deﬁned our regions of interest. Median grey matter
cerebral blood ﬂow was extracted from each region of interest
for subsequent regional analyses within the overall group, as
well as stratiﬁed between genetic subgroups. The region of
interest analyses evaluated whether there were differences in
the associations linking extracted cerebral blood ﬂow with
years to age of expected symptom onset between presympto-
matic carriers and non-carriers using linear mixed models,
taking into account ﬁxed effects of sex and site, and random
effects of family membership as covariates. To test if there
were non-linear changes in cerebral blood ﬂow, we also
tested a quadratic term for years to age of expected symptom
onset. Sensitivity analyses were performed by repeating the
analysis with age replacing years to age of expected symptom
onset and after a high-only winsorization of 0 to 10 values of
cerebral blood ﬂow to account for cerebral blood ﬂow outliers.
Partial volume correction
We implemented a partial volume correction to mitigate any
regional tissue differences that would act as a confound
(Asllani et al., 2008). Region of interest analyses were per-
formed with and without the partial volume correction. Since
the regions of interest were derived from the voxel-based ana-
lysis, which was restricted to the grey matter, they were dilated
centrally to include sufﬁcient white matter voxels for a robust
partial volume correction. Speciﬁcally, the region of interest
was eroded in volume until the white matter voxels accounted
for 550% of the total volume. As a result of differences in
effective resolution and smoothness between ASL sites
(Mutsaerts et al., 2018), we estimated the effective spatial reso-
lution based on the different ASL implementations (Vidorreta
et al., 2013; Mutsaerts et al., 2018), which could contribute to
partial volume error. We assumed the following effective reso-
lutions in FWHM: 3.7  3.7  7.6mm (2D EPI with back-
ground suppression), 4.6  4.6  4.3mm (2D EPI without
background suppression), 3.75  3.75  5.5mm (3D
GRASE) (Vidorreta et al., 2013), 5.0  5.0  9.5mm (3D
spiral).
Timing of cerebral blood flow decline
Instead of stratifying years to age of expected symptom onset
at regular time points, e.g. 5- or 10-year intervals, we used a
quantile approach to account for the high physiological cere-
bral blood ﬂow variability on an individual basis by ensuring
equal numbers of participants per time interval. Subsequently,
the association between quantiles of years to age of expected
symptom onset and cerebral blood ﬂow was tested using linear
mixed models, adjusting for sex and site (ﬁxed effects), and
family (random effects) as covariates in presymptomatic non-
carriers and carriers separately. In these models, the quantile
variable was used as a categorical predictor variable with the
ﬁrst quantile as the reference quantile. We tested quintiles,
sextiles, septiles, octiles, and deciles to ensure robustness of
results. Since octiles enabled us to explore smaller intervals
with a reasonable number of participants per interval to
obtain valid estimates, we present results for octiles only.
Secondary analysis comparing
symptomatic and presymptomatic
mutation carriers
To understand the perfusion data further, we compared cere-
bral blood ﬂow in mutation carriers who were symptomatic
(n = 31) to those who remained presymptomatic past their ex-
pected age of symptom onset (n = 23). This was done using t-
tests and linear regression models adjusted for age and sex of
participants. This analysis used cerebral blood ﬂow that was
extracted from within the voxel-based deﬁned regions of inter-
est as described previously. As we were interested in compar-
ing cerebral blood ﬂow in symptomatic versus presymptomatic
carriers who were beyond their expected age of symptom
onset, we excluded all non-carriers, presymptomatic carriers
who did not meet this criterion, and one symptomatic muta-
tion carrier who had a very high cerebral blood ﬂow value in
the left supramarginal/angular gyri, thus considered an outlier.
Data availability
Data will be shared according to the GENFI data sharing
agreement, after review by the GENFI data access committee
with ﬁnal approval granted by the GENFI steering committee.
Results
Demographic, cognitive and
behavioural measures and family
distribution across sites
Apart from mutation carriers being younger than non-car-
riers, no signiﬁcant differences in demographic, general
cognitive and behavioural measures were observed between
the two groups (Table 1). Supplementary Fig. 1 provides an
overview of the family distribution across the different sites
for all participants. Site and family membership were
strongly related, but nonetheless were considered as covari-
ates due to the importance of both of these factors.
Brain perfusion in frontotemporal dementia BRAIN 2019: 142; 1108–1120 | 1113
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1108/5371511 by Erasm
us U
niversity R
otterdam
 user on 24 July 2019
Voxel-based analysis
Years to age of expected symptom onset predicted a lower
cerebral blood ﬂow due to decline in perfusion with age.
While no main effect of carrier status on cerebral blood
ﬂow was observed, we identiﬁed a robust and statistically
signiﬁcant carrier status  years to age of expected symp-
tom onset interaction. Speciﬁcally, as shown by Table 2
and Fig. 1, we identiﬁed several regions with a signiﬁcantly
greater inverse association between cerebral blood ﬂow and
the expected age of symptom onset in presymptomatic mu-
tation carriers compared to non-carriers. Six regions were
identiﬁed by the voxel-based analysis including: the left
middle temporal gyrus, bilateral anterior cingulate/paracin-
gulate gyri, bilateral anterior insula/orbitofrontal gyri, and
bilateral supramarginal/angular gyri. The peak t-statistics
were higher for clusters in the right hemisphere compared
to the left hemisphere for the anterior insula/orbitofrontal
gyri (t = 5.2 versus t = 4.8), supramarginal/angular gyri
(t = 5.8 versus t = 4.6) and for the anterior cingulate/para-
cingulate cortex (t = 4.6 versus t = 3.9).
Regions of interest analysis
Table 3 shows the difference in association of cerebral
blood ﬂow with years to age of expected symptom onset
between presymptomatic carriers and non-carriers within
the voxel-based analysis-deﬁned regions of interest in the
overall group and stratiﬁed for genetic subgroup, with and
without partial volume correction. The main effect of years
to age of expected symptom onset and the interaction effect
of years to age of expected symptom onset  carrier status
were signiﬁcantly associated with cerebral blood ﬂow in all
regions of interest, with the exception of the right supra-
marginal/angular gyri wherein only the interaction term
was signiﬁcant. These results were consistent before and
after partial volume correction in the entire cohort. In ana-
lyses without partial volume correction applied, all genetic
subgroups contributed to the main effect of years to age of
expected symptom onset. However, after partial volume
correction was applied, results seemed to be largely
driven by the C9orf72 group. The interaction between
years to age of expected symptom onset and carrier
status was only found in the C9orf72 group after applying
partial volume correction.
The quadratic term for years to expected age of symptom
onset was not signiﬁcant and did not improve the model ﬁt,
therefore, it was not included in the model. In a sensitivity
analysis, when years to age of expected symptom onset was
replaced by age, the same clusters survived, albeit to a
lesser extent. The regional analysis was also repeated
with age instead of years to age of expected symptom
onset and after high-only winsorization of zero to 10
values to account for cerebral blood ﬂow outliers, which
did not change the results.
Estimation of time of cerebral blood
flow decline
In the analyses of octiles of years to age of expected symp-
tom onset and cerebral blood ﬂow in the entire cohort, we
observed that cerebral blood ﬂow in carriers started to
differ signiﬁcantly from the fourth octile onward (corres-
ponding to 14.8 to 9.3 years) compared to the ﬁrst
octile, which was used as a reference (40.9 to 25.1
years). This means that on average, the change in cerebral
blood ﬂow in presymptomatic carriers starts to occur at
12.5 years before their expected years to age of symptom
onset. This pattern was observed for all regions of interest
(Supplementary Tables 1 and 2) in presymptomatic muta-
tion carriers only. No differences in cerebral blood ﬂow
between the octiles were observed in non-carriers
(Supplementary Tables 1 and 2, and Fig. 2). Figure 2 rep-
resents cerebral blood ﬂow decline in presymptomatic car-
riers and non-carriers over years to age of expected
symptom onset in each of the identiﬁed voxel-based ana-
lysis-deﬁned regions of interest. Carriers who were several
years away from their age of predicted symptom onset had
higher cerebral blood ﬂow values than non-carriers with
similar years to age of expected symptom onset. In con-
trast, carriers who were beyond their age of expected symp-
tom onset had lower cerebral blood ﬂow values than non-
carriers with similar years to age of expected symptom
onset. This resulted in a steeper negative slope of the re-
gression lines for each region of interest in carriers than in
Table 2 Anatomical localization of voxel-based analysis-derived clusters of cerebral blood flow
Cluster Cluster size (ml) Peak t-score Peak MNI coordinates (mm)
x y z
L middle temporal gyrus 4.2 4.4 60.0 33.0 1.5
B anterior cingulate/paracingulate gyri 12.8 4.6 + 9.0 + 54.0 9.0
R anterior insula, orbitofrontal gyri 7.8 5.2 + 42.0 + 22.5 10.5
L anterior insula, orbitofrontal gyri 2.6 4.3 30.0 + 25.5 7.5
R supramarginal/angular gyri 4.0 5.9 + 63.0 55.5 + 6.0
L supramarginal/angular gyri 2.8 4.6 52.5 63.0 + 9.0
Clusters for the cerebral blood flow interaction between age to expected symptom onset and mutation carrier status, for primary cluster-forming threshold P = 0.005 and FWE
threshold P = 0.05. B = bilateral; L = left; R = right.
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non-carriers, which remained consistent after we repeated
our analyses with mean-centred cerebral blood ﬂow values.
A similar pattern of results was observed across all regions
of interest.
Secondary analysis comparing
symptomatic and presymptomatic
mutation carriers
While mean cerebral blood ﬂow values were always lower
in symptomatic carriers (demographic characteristics in
Supplementary Table 3) than in presymptomatic carriers
who were beyond their expected age of symptom onset
(Supplementary Table 4), this association only reached stat-
istical signiﬁcance in the bilateral cingulate and insulae/
orbitofrontal gyri, as well as the left supramarginal/angular
gyri. Linear regression models also showed similar results
after adjusting for age and sex (Supplementary Table 5).
Discussion
This multicentre GENFI ASL perfusion study has identiﬁed
frontal, temporal and parietal brain regions where cerebral
blood ﬂow is altered among presymptomatic frontotem-
poral dementia mutation carriers compared to non-carrier
family members. We found some evidence of a laterality
effect, whereby the right hemisphere appeared to be more
affected than the left hemisphere in the frontoparietal re-
gions. The speciﬁc brain regions detected include: the
medial frontal cortex, speciﬁcally the bilateral anterior cin-
gulate and paracingulate gyri; the orbitofronto-insular
cortex bilaterally; the inferior parietal region, speciﬁcally
the bilateral supramarginal and angular gyri; and the left
middle temporal gyrus. Our important and novel ﬁndings
are highlighted by the following. First, presymptomatic mu-
tation carriers were slightly younger than non-carriers, fur-
ther strengthening the premise that the mutations, in
combination with expected age at symptom onset, had a
greater impact on cerebral perfusion than age alone.
Second, adjusting for potential atrophy effects through par-
tial volume correction did not inﬂuence the gene carrier to
cerebral blood ﬂow associations, but nonetheless seemed to
implicate a stronger cerebral blood ﬂow inﬂuence for the
C9orf72 carriers compared to the GRN and MAPT gene
carrier subgroups. Third, the lower regional cerebral blood
ﬂow in presymptomatic mutation carriers based on age
from estimated time of symptom onset occurred approxi-
mately 12.5 years before the average age of onset of symp-
toms in affected family members, albeit from a higher
baseline level of cerebral blood ﬂow. In presymptomatic
carriers compared to non-carriers, the slight increase in
cerebral blood ﬂow seen between octile 9.1 to 4.7
years may represent a rebound phenomenon. It is conceiv-
able that in order to preserve behaviour, cognition and
function as an individual approaches their expected age
of symptom onset, there may be a compensatory rise in
cerebral blood ﬂow before it becomes more severely deﬁ-
cient. Alternatively, this may simply be the result of natural
variation in cerebral blood ﬂow and an artefact of the
cross-sectional analysis performed here. This phenomenon
will be explored in more detail in future longitudinal ana-
lyses correlating it with changes in behavioural and cogni-
tive performance. Fourth, in a secondary analysis,
presymptomatic carriers who were beyond their expected
age of symptom onset had relatively higher regional cere-
bral blood ﬂow than symptomatic carriers indicating the
potential protective effects of preserved cerebral blood
ﬂow with respect to delaying symptom onset.
These ﬁndings demonstrate the potential utility of non-
invasive perfusion MRI as an early imaging biomarker for
genetic forms of frontotemporal dementia during the
presymptomatic phase. The medial frontal and orbito-
fronto-insular regions of hypoperfusion identiﬁed as pre-
symptomatic carriers approached their expected age of
symptom onset in this study overlap with regions of atro-
phy identiﬁed in our previous neuroanatomical study (Cash
et al., 2018). These regions are part of a distributed net-
work previously shown to be involved in aberrant socio-
emotional processing observed in frontotemporal dementia.
Speciﬁcally, the anterior insula is a critical hub region that,
together with the dorsal anterior cingulate cortex, form
part of the salience network and the paralimbic system
involved in cognitive, sensory and affective regulation
(Menon, 2015). The orbitofrontal cortex receives limbic
projections from the cingulate and parahippocampal cor-
tices, hippocampus and amygdala and also receives innerv-
ation from all the sensory modalities, thus integrating
sensory, memory and emotional information (Viskontas
et al., 2007). Anatomically, it transitions into the insula
via the frontoinsular cortex, which is an agranular region
that contains von Economo neurons (Seeley, 2010). This
neuronal cell type is also present in the anterior cingulate
cortex further strengthening the cytoarchitectonic link be-
tween these two cortical regions (Seeley, 2010).
Accumulating evidence indicates that von Economo neu-
rons may be most susceptible early on to neuropathological
and degenerative processes involved in frontotemporal de-
mentia (Seeley et al., 2006), leading some to posit that this
cell type is responsible for the early regional vulnerability of
the anterior cingulate and insular cortices (Seeley et al.,
2007). With respect to clinical phenotype, behavioural vari-
ant frontotemporal dementia is nearly four times as
common as presentations with primary progressive aphasia
(Hogan et al., 2016). The reason for this observation is not
known, but the rightward, regional frontal involvement
seen in the current study overlaps with ﬁndings in studies
of symptomatic frontotemporal dementia. Speciﬁcally, prior
imaging (Miller et al., 1993; Mychack et al., 2001;
Schroeter et al., 2007; Gordon et al., 2016) and patho-
logical case series (Irwin et al., 2018) have shown regional
involvement of the anterior cingulate/paracingulate, orbito-
frontal and/or anterior insular cortices with a right
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hemispheric predilection for behavioural variant frontotem-
poral dementia. Based on our ﬁndings in the context of
existing literature, we anticipate that the majority of our
presymptomatic cohort would be predisposed to develop
behavioural variant frontotemporal dementia, which is the
subject of future study using longitudinal GENFI data. If
the theory of vulnerability via von Economo neurons in
early stage frontotemporal dementia is correct, then the
right-predominant hemispheric involvement in frontotem-
poral dementia may be related to the higher number of
susceptible von Economo neurons in the right anterior
insula and anterior cingulate cortex than on the left in
post-natal brains (Allman et al., 2011).
Hypoperfusion was also seen in the left middle temporal
gyrus in presymptomatic carriers in relation to their ex-
pected age of symptom onset. The posterior aspect of this
structure is strongly connected to the left inferior frontal
gyrus, and together they contribute to controlled semantic
retrieval (Davey et al., 2015). A quantitative meta-analysis
has revealed that the semantic variant of primary progres-
sive aphasia is associated with grey matter atrophy invol-
ving the bilateral inferior temporal and fusiform gyri, the
medial aspect of the temporal lobes (including parahippo-
campal gyri and amygdala), as well as the left temporal
pole, middle temporal gyrus, and caudate (Yang et al.,
2012). Whether or not presymptomatic mutation carriers
who have prominent hypoperfusion involving the left
middle temporal gyrus will go on to develop clinical fea-
tures of semantic dementia will have to be determined
through longitudinal monitoring of the GENFI cohort.
The inferior parietal lobule bilaterally showed lower per-
fusion in presymptomatic carriers compared to non-carriers
in association with their expected age at symptom onset.
This structure is made up of the supramarginal (rostral
portion) and angular (caudal portion) gyri, and through
connections with frontal, temporal and occipital cortex, it
is important for sensorimotor integration (Caspers et al.,
2013). In the left hemisphere, the inferior parietal lobule
is part of the dorsal stream for auditory perception playing
a role in verbal working memory, phonological short term
memory, and temporal ordering of articulation and sound
(Binkofski et al., 2016). It is also involved in motor func-
tions and interactions with objects (Binkofski et al., 2016).
The left angular gyrus is involved in reading, writing,
verbal repetition, naming, processing of semantic content
and contributes to modality-independent conceptual and
semantic processes linking language and action networks
(Binkofski et al., 2016). In the right hemisphere, the rostral
and middle inferior parietal lobule is involved in spatial
coding and attention, as well as learning and execution of
complex sequential motor movements, including those
involved in multi-tool/object use (Binkofski et al., 2016).
Bilaterally, the rostral inferior parietal lobule forms part
of the ventrodorsal stream of visual perception involved
in sensorimotor information processing based on object
use representations; lesions to this structure can impair
both pantomime and real object use resulting in limb
apraxia (Binkofski et al., 2016). On the right side, the an-
gular gyrus is involved in spatial functions with lesions of
this structure producing hemi-neglect (Binkofski et al.,
2016). There is evidence of atrophy, reduced functional
connectivity and perfusion, and pathological involvement
of the inferior parietal lobule that correlates with disturb-
ances in language and praxis observed in GRN-related
frontotemporal dementia (Rohrer et al., 2010; Seelaar
et al., 2011a; Premi et al., 2014; Kim et al., 2016).
Therefore, it is possible that the presymptomatic GRN car-
riers in this study might be driving our observed cerebral
blood ﬂow association with the inferior parietal lobule, al-
though we did not have the power to assess this directly.
Interestingly, as illustrated in Fig. 2, presymptomatic mu-
tation carriers tended on average to have higher perfusion
than non-carriers several years before their predicted age of
symptom onset, but carriers who were beyond their pre-
dicted age of symptom onset tended to have lower perfu-
sion than their non-carrier counterparts in the same time
period. This raises the possibility that compensatory mech-
anisms involving cerebral perfusion may be at work early
during the presymptomatic phase in mutation carriers to
maintain normal brain functions. Compensatory mechan-
isms have been hypothesized to be at play in young
APOE "4 allele carriers at risk for Alzheimer’s disease
using both resting state and task-based functional MRI
demonstrating increased default mode network connectivity
at rest and during an encoding task compared to their non-
carrier counterparts (Filippini et al., 2009). However, a
more recent ASL perfusion MRI study in cognitively
normal older adults carrying the APOE "4 allele demon-
strated increased perfusion involving the medial frontal
cortex, medial and lateral temporal cortex, parietal regions,
insula, and the basal ganglia that was associated with
worse verbal memory functions (Zlatar et al., 2016).
Other than the use of different functional imaging modal-
ities, it is possible that the conﬂicting observations might be
due to differences in the age of the participants included in
the two studies. For example, compensatory mechanisms
may start to break down in older APOE "4 participants
due to increasing age as Alzheimer’s brain pathological
burden becomes more prominent and we hypothesize a
similar process may be seen in autosomal dominant fron-
totemporal dementia. Data presented in Fig. 2 and
Supplementary Table 1 should be interpreted with caution
as they do not compare carriers to non-carriers directly.
However, both show different cerebral blood ﬂow trajec-
tories in carriers and non-carriers indicating a similar time
window of cerebral blood ﬂow decline in carriers in all
regions.
Whilst we did not have sufﬁcient statistical power to
identify regions of hypoperfusion in mutation carriers stra-
tiﬁed by genetic subgroup in independent voxel-based ana-
lyses, the post hoc regions of interest analysis produced
some noteworthy results. Firstly, C9orf72 and MAPT mu-
tation carriers showed the observed inverse association be-
tween cerebral blood ﬂow and years to age of expected
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symptom onset in all six regions identiﬁed from the original
combined group analysis, whereas GRN mutation carriers
only showed this effect in the bilateral anterior cingulate/
paracingulate, right anterior insula/orbitofrontal, and right
supramarginal/angular gyri. This ﬁnding is in line with pre-
vious literature demonstrating that GRN mutations lead to
asymmetric involvement of the brain (Masellis et al., 2006;
Gabryelewicz et al., 2010; Rohrer and Warren, 2011),
whereas both MAPT and C9orf72-related frontotemporal
dementia tends to present with more symmetrical brain
ﬁndings (Rohrer and Warren, 2011; Mahoney et al.,
2012). Finally, only the C9orf72 mutation carriers
showed persistent perfusion deﬁcits after partial volume
correction in all regions of interest. This suggests that
early presymptomatic perfusion anomalies in C9orf72 mu-
tation carriers are robust and not as signiﬁcantly inﬂuenced
by underlying structural changes in the same cortical re-
gions. These regional presymptomatic perfusion deﬁcits
are consistent with the known slowly progressive behav-
ioural and neuropsychiatric symptoms that occur over
many years in C9orf72 mutation carriers (Khan et al.,
2012; Galimberti et al., 2013; Devenney et al., 2014).
Because of the multicentre nature of this study, one of the
main strengths is that we were able to acquire the largest
ASL sample, to date, of presymptomatic individuals at-risk
for genetic frontotemporal dementia. However, one draw-
back of multicentre ASL studies is variability from MRI
vendor and/or sequence acquisition procedures (Alsop
et al., 2015). We attempted to mitigate nuisance effects
through the use of a robust ASL software package
(Mutsaerts et al., 2018), which included partial volume
error correction (Mutsaerts et al., 2014), intensity normal-
ization, and semi-automatic quality control (Mutsaerts
et al., 2017). This has allowed GENFI to overcome the
current status quo in ASL imaging studies of neurodegen-
erative diseases that restricts analyses to those scanned on
the same MRI platform, such as what is done in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) and
Parkinson’s Progression Marker Initiative (PPMI); this sig-
niﬁcantly limits ASL sample sizes to only a subset of par-
ticipants in those studies. Another strength is that we
included Family as a random factor in our linear mixed-
effect models to account for effects of both unknown gen-
omic or environmental inﬂuences that may co-vary with
cerebral perfusion changes in the participants. Limitations
include the relatively small sample size of the genetic sub-
groups, which reduced power in subgroup analyses.
However, through our use of a voxel-based analysis in
the entire cohort to identify regions of interest with subse-
quent post hoc analysis restricted to these regions, we have
been able to detect some genetic subgroup differences.
Another challenge of using the ASL MRI technique is
that physiological perfusion ﬂuctuations are high on both
an intra- and interindividual basis. For example, diurnal
effects, drug effects, and post-prandial state have been
shown to inﬂuence perfusion (Clement et al., 2017). This
may limit the discovery of small neurovascular coupling-
related effects to studies with large sample sizes.
Cerebral blood ﬂow was inversely associated with an in-
dividual’s expected age of symptom onset in presympto-
matic mutation carriers compared to non-carriers, in
signature regions previously implicated in symptomatic
frontotemporal dementia. The regional analyses that
applied partial volume correction suggest that these effects
were most signiﬁcant in C9orf72 hexanucleotide repeat ex-
pansion carriers. These results make ASL MRI promising
as a non-invasive imaging biomarker for the presympto-
matic stages of genetic frontotemporal dementia. Future
work will focus on longitudinal analysis, as well as at-
tempting to identify other factors that lead to phenoconver-
sion to symptomatic frontotemporal dementia. Therapeutic
strategies that can preserve or improve cerebral blood ﬂow
may hold promise in preventing or delaying symptom
onset, respectively, in at-risk presymptomatic mutation car-
riers, or potentially reversing symptoms in early symptom-
atic stages of frontotemporal dementia.
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